How Does the In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach Publication How Does the In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach Information on the developmental changes in biliary excretion (BE) of drugs is sparse. The aims…Certara2016 年 7 月 1 日
Considering Age Variation When Coining Drugs as High Versus Low Hepatic Extraction Ratio Publication Considering Age Variation When Coining Drugs as High Versus Low Hepatic Extraction Ratio The hepatic extraction ratio (EH) is commonly considered an "inherent attribute" of drug. It determines…Certara2016 年 7 月 1 日
Lessons Learned: Dose Selection of Small Molecule-targeted Oncology Drugs Publication Lessons Learned: Dose Selection of Small Molecule-targeted Oncology Drugs Certara2016 年 6 月 1 日
Pharmacokinetics and Tissue Elimination of Funixin in Veal Calves Publication Pharmacokinetics and Tissue Elimination of Funixin in Veal Calves OBJECTIVE To describe plasma pharmacokinetic parameters and tissue elimination of flunixin in veal calves. ANIMALS…Certara2016 年 6 月 1 日
Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data Publication Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal…Certara2016 年 6 月 1 日
Can QSP Save Lives? Lessons from the Bial Trial Debacle On-Demand Webinar Can QSP Save Lives? Lessons from the Bial Trial Debacle One of the biggest challenges for the pharmaceutical industry is the high rate of drug…Certara2016 年 5 月 4 日
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Kinetics in Medullary Thyroid Cancer Patients Receiving Cabozantinib Publication Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Kinetics in Medullary Thyroid Cancer Patients Receiving Cabozantinib Nonlinear mixed effects models were developed to describe the relationship between cabozantinib exposure and target…Certara2016 年 4 月 27 日
Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates with Estron e-3-Sulfate Transport in Caco-2 Publication Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates with Estron e-3-Sulfate Transport in Caco-2 Transporter mRNA and protein expression data are used to extrapolate in vitro transporter kinetics to in…Certara2016 年 4 月 1 日
Population Pharmacokinetic and Pharmacodynamic Analyses from a 4-Month Intra-dose Escalation and Its Subsequent 12-month Dose Titration Studies for a Human Monoclonal Anti-FGF23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia Publication Population Pharmacokinetic and Pharmacodynamic Analyses from a 4-Month Intra-dose Escalation and Its Subsequent 12-month Dose Titration Studies for a Human Monoclonal Anti-FGF23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia X-linked hypophosphatemia (XLH) is an inherited metabolic bone disease with abnormally elevated serum FGF23 resulting…Certara2016 年 4 月 1 日
Population Pharmacokinetics and Exposure-response of Trametinib, a MEK Inhibitor, in Patients with BRAF V600 Mutation-positive Melanoma Publication Population Pharmacokinetics and Exposure-response of Trametinib, a MEK Inhibitor, in Patients with BRAF V600 Mutation-positive Melanoma The purpose of this study was to characterize the pharmacokinetics of oral trametinib, a first in…Certara2016 年 4 月 1 日